Four-year follow-up of inflammatory arthropathy patients treated with golimumab: Data from the observational multicentre NOR-DMARD study

Brigitte Michelsen; Joseph Sexton; Ada Wierød; Gunnstein Bakland; Erik Rødevand; Frode Krøll; Tore K Kvien

doi:10.1016/j.semarthrit.2019.07.003

Four-year follow-up of inflammatory arthropathy patients treated with golimumab: Data from the observational multicentre NOR-DMARD study

Semin Arthritis Rheum. 2020 Feb;50(1):12-16. doi: 10.1016/j.semarthrit.2019.07.003. Epub 2019 Jul 12.

Authors

Brigitte Michelsen¹, Joseph Sexton², Ada Wierød³, Gunnstein Bakland⁴, Erik Rødevand⁵, Frode Krøll⁶, Tore K Kvien²

Affiliations

¹ Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway; Division of Rheumatology, Department of Medicine, Hospital of Southern Norway Trust, Kristiansand, Norway. Electronic address: brigitte_michelsen@yahoo.no.
² Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway.
³ Department of Rheumatology, Vestre Viken/ Drammen Hospital, Drammen, Norway.
⁴ Department of Rheumatology, University Hospital of Northern Norway, Tromsø, Norway.
⁵ Department of Rheumatology, St. Olavs Hospital, Trondheim, Norway.
⁶ Department of Rheumatology, Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway.

PMID: 31358361
DOI: 10.1016/j.semarthrit.2019.07.003

Abstract

Objective: To compare (1) golimumab drug survival and efficacy in bDMARD naïve compared with non-naïve rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondyloarthritis (ax-SpA) patients, (2) golimumab drug survival in RA and PsA patients treated with/without concomitant csDMARDs, (3) predictors of golimumab drug discontinuation.

Methods: Patients starting golimumab were included from the prospective observational multicenter Norwegian DMARD study. Drug survival was explored by Kaplan-Meier analyses with log rank test. Treatment responses were compared using ANCOVA. Univariate and multivariate Cox regression analyses were performed to identify predictors of golimumab discontinuation.

Results: We included 808 patients (163 RA, 266 PsA, 379 ax-SpA). Golimumab drug survival after 1/2/4 years were not significantly different between bDMARD naïve and non-naïve patients (all, p ≥ 0.12; RA, p ≥ 0.07; PsA, p ≥ 0.28; ax-SpA, p ≥ 0.61), nor between RA (p ≥ 0.10) and PsA (p ≥ 0.07) patients treated with vs. without csDMARD comedication. bDMARD naïve compared with non-naïve ax-SpA patients had better 3-month ASDAS/BASDAI/MHAQ responses (p ≤ 0.02). bDMARD naïve compared with non-naïve RA and PsA patients had a trend towards better treatment responses. Identified predictors of 4-year golimumab discontinuation were patient's global and female gender in patients overall and in subgroups of PsA and ax-SpA patients, and patient's global and CRP in RA.

Conclusion: Golimumab drug survival was not significantly different between bDMARD naïve and non-naïve RA, PsA and ax-SpA patients, nor between RA and PsA patients treated with vs. without concomitant csDMARDs. Treatment responses were significantly better for bDMARD naïve than non-naïve ax-SpA patients. Identified predictors of golimumab discontinuation were patient's global and female gender in patients overall and in subgroups of PsA and ax-SpA patients, and patient's global and CRP in RA.

Keywords: Biological therapy; Psoriatic arthritis; Rheumatoid arthritis; Spondylarthritis.

Publication types

Multicenter Study
Observational Study
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Aged
Antibodies, Monoclonal / therapeutic use*
Antirheumatic Agents / therapeutic use*
Arthritis, Psoriatic / drug therapy*
Arthritis, Rheumatoid / drug therapy*
Biological Products / therapeutic use*
Female
Follow-Up Studies
Humans
Male
Middle Aged
Spondylarthritis / drug therapy*
Treatment Outcome

Substances

Antibodies, Monoclonal
Antirheumatic Agents
Biological Products
golimumab